novo nordisk weight loss

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.

Reuters · 5h

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

AOL · 21h

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk, NVO

Insider Monkey on MSN · 2h

Why Novo Nordisk (NVO) Is Climbing Today

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported higher-than-expected net income for the fourth quarter.

The Wall Street Journal on MSN · 4h

Novo Nordisk Outlook Provides Some Welcome Relief

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing capacity constraints and fears over the U.S. demand outlook for Wegovy.

Business Insider · 6h

Novo Nordisk (NVO) Receives a Buy from TD Cowen

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s

Wegovy sales double to boost Novo Nordisk's 4th quarter

AOL · 3h

Novo Nordisk beats on Wegovy sales, expects slower 2025 growth

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.

Investopedia on MSN · 7h

Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition.

Reuters on MSN · 3h

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Yahoo Finance12d

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product ...

Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

23hon MSN

Healthy Returns: Why people quit weight loss, diabetes drugs within one year

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Novo Nordisk Shares Have a Long Road Back from 40% Slump

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results